Lev Sirota
Overview
Explore the profile of Lev Sirota including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kachko A, Frey S, Sirota L, Ray R, Wells F, Zubkova I, et al.
Hepatology
. 2015 Aug;
62(6):1670-82.
PMID: 26251214
Unlabelled: Hepatitis C virus (HCV) neutralization occurring at the E2 region 412-426 (EP-I) could be enhanced when antibodies directed specifically to the E2 region 434-446 (EP-II) were removed from serum...
2.
Dominguez-Castillo R, Verma A, Amador-Molina J, Sirota L, Arciniega J
Biologicals
. 2012 Nov;
41(2):111-4.
PMID: 23137818
We examined the capability of a mouse immunogenicity assay to detect improper storage of a recombinant protective antigen (rPA)-based anthrax vaccine formulated with an aluminum adjuvant, using ELISA and a...
3.
Zaitseva M, Romantseva T, Blinova K, Beren J, Sirota L, Drane D, et al.
Vaccine
. 2012 May;
30(32):4859-65.
PMID: 22609036
Subunit vaccines composed of recombinant or purified antigens have a good safety record but are poorly immunogenic and require adjuvants to activate innate immunity and facilitate antigen specific immune response....
4.
Jimenez-Alberto A, Parreiras P, Castelan-Vega J, Sirota L, Arciniega J
Biologicals
. 2011 Jun;
39(4):236-41.
PMID: 21664832
Complexities of lethal challenge animal models have prompted the investigation of immunogenicity assays as potency tests of anthrax vaccines. An ELISA was used to measure the antibody response to protective...
5.
Castelan-Vega J, Corvette L, Sirota L, Arciniega J
Clin Vaccine Immunol
. 2010 Dec;
18(2):349-51.
PMID: 21147935
We report that a toxin neutralization assay (TNA) can detect a decrease in the immunogenicity of anthrax vaccines as a consequence of brief exposure to elevated temperature. This attribute of...
6.
Zaitseva M, Kapnick S, Scott J, King L, Manischewitz J, Sirota L, et al.
J Virol
. 2009 Aug;
83(20):10437-47.
PMID: 19656894
To find an alternative endpoint for the efficacy of antismallpox treatments, bioluminescence was measured in live BALB/c mice following lethal challenge with a recombinant WR vaccinia virus expressing luciferase. Intravenous...
7.
Rubin S, Qi L, Audet S, Sullivan B, Carbone K, Bellini W, et al.
J Infect Dis
. 2008 Jun;
198(4):508-15.
PMID: 18558869
Recent mumps outbreaks in older vaccinated populations were caused primarily by genotype G viruses, which are phylogenetically distinct from the genotype A vaccine strains used in the countries affected by...
8.
He Y, Manischewitz J, Meseda C, Merchlinsky M, Vassell R, Sirota L, et al.
J Infect Dis
. 2007 Sep;
196(7):1026-32.
PMID: 17763325
The smallpox vaccine Dryvax, which consists of replication-competent vaccinia virus, elicits antibodies that play a major role in protection. Several vaccinia proteins generate neutralizing antibodies, but their importance for protection...
9.
Pal A, Sirota L, Maudru T, Peden K, Lewis Jr A
J Virol Methods
. 2006 Mar;
135(1):32-42.
PMID: 16527364
Mixtures of polyomaviruses can be present in the central nervous system, the gastrointestinal tract, the genitourinary tract, blood, and urban sewage. We have developed 12 primer/probe sets (four per virus)...
10.
Desmezieres E, Gupta N, Vassell R, He Y, Peden K, Sirota L, et al.
J Virol
. 2005 Mar;
79(8):4774-81.
PMID: 15795263
Human immunodeficiency virus (HIV) infects cells by fusing with cellular membranes. Fusion occurs when the envelope glycoprotein (Env) undergoes conformational changes while binding to cellular receptors. Fusogenic changes involve assembly...